retatrutide phase 2 obesity trial results Early data for demonstrates exceptional weight loss results, reaching approximately 21% placebo-adjusted weight loss by week 48. This performance significantly exceeds all other leading medications currently under Lilly's triple agonist delivers up

However, this did not alter the main findings (Fig

Zepbound is FDA-approved as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity

Regular physical activity, adequate nutrition, consistent sleep and social support can all contribute to maintaining energy and motivation during weight loss

Suitability for peptide-based injectable therapy

It's a tailored approach

Eli Lilly says that Zepbound is a dual receptor agonist that targets both GIP and GLP-1 receptors, unlike other incretins approved for obesity management, which target only GLP-1 receptors. And Novo Nordisk says that Wegovy has the broadest GLP-1 label, including indications for reducing risk of major adverse cardiovascular events in some patients and for treatment of a certain liver condition in some adults